Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function

Biochemical and Biophysical Research Communications

Volumn 413, Issue 2, 2011, Pages 194-200

  Moon, Ho Jin ^a   Yun, Young Pil ^a   Han, Choong Wan ^a   Kim, Min Sung ^a   Kim, Sung Eun ^a   Bae, Min Soo ^a   Kim, Gyu Tae ^a   Choi, Yong Suk ^a   Hwang, Eui Hwan ^a   Lee, Joon Woo ^b   Lee, Jin Moo ^a   Lee, Chang Hoon ^a   Kim, Duck Su ^a   Kwon, Il Keun ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Science and Technology Information (KISTI)   (South Korea)

Author keywords

Alendronate; Heparin; Osteoblast; Osteoclast; Titanium

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; CATHEPSIN K; HEPARIN; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; TITANIUM;

ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; IN VITRO STUDY; MATERIAL COATING; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ALENDRONATE; ANIMALS; CELL LINE; COATED MATERIALS, BIOCOMPATIBLE; HEPARIN; MICE; OSTEOBLASTS; OSTEOCLASTS; RANK LIGAND; SURFACE PROPERTIES; TITANIUM;

EID: 80053096768     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.057     Document Type: Article

References (29)

1. Brunette D., Tengvall P., Textor M., Thomsen P. Titanium in Medicine 2001, Springer Verlag, Berlin, Heidelberg.
2. Albrektsson T., Wennerberg A. Oral implant surfaces: Part 1- review focusing on topographic and chemical properties of different surfaces and in vivo responses to them. Int. J. Prosthodont. 2004, 17:536-543.
3. Albrektsson T., Wennerberg A. Oral implant surfaces: Part 2 - review focusing on clinical knowledge of different surfaces. Int. J. Prosthodont. 2004, 17:544-564.
4. Schwartz Z., Boyan B.D. Underlying mechanisms at the bone-biomaterial interface. J. Cell. Biochem. 1994, 56:340-347.
5. Le Guehennec L., Soueidan A., Layrolle P., Amouriq Y. Surface treatments of titanium dental implants for rapid osseointegration. Dent. Mater. 2007, 23:844-854.
6. Steinemann S.G. Titanium--the material of choice?. Periodontol 2000 1998, 17:7-21.
7. Michael J., Schonzart L., Israel I., Beutner R., Scharnweber D., Worch H., Hempel U., Schwenzer B. Oligonucleotide-RGD peptide conjugates for surface modification of titanium implants and improvement of osteoblast adhesion. Bioconjug. Chem. 2009, 20:710-718.
8. Oya K., Tanaka Y., Saito H., Kurashima K., Nogi K., Tsutsumi H., Tsutsumi Y., Doi H., Nomura N., Hanawa T. Calcification by MC3T3-E1 cells on RGD peptide immobilized on titanium through electrodeposited PEG. Biomaterials 2009, 30:1281-1286.
9. Shin H., Jo S., Mikos A.G. Biomimetic materials for tissue engineering. Biomaterials 2003, 24:4353-4364.
10. Wang E.A., Rosen V., D'Alessandro J.S., Bauduy M., Cordes P., Harada T., Israel D.I., Hewick R.M., Kerns K.M., LaPan P., et al. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. USA 1990, 87:2220-2224.
11. Cook S.D., Wolfe M.W., Salkeld S.L., Rueger D.C. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J. Bone Joint Surg. Am. 1995, 77:734-750.
12. Kim S.E., Jeon O., Lee J.B., Bae M.S., Chun H.J., Moon S.H., Kwon I.K. Enhancement of ectopic bone formation by bone morphogenetic protein-2 delivery using heparin-conjugated PLGA nanoparticles with transplantation of bone marrow-derived mesenchymal stem cells. J. Biomed. Sci. 2008, 15:771-777.
13. Govender S., Csimma C., Genant H.K., Valentin-Opran A., Amit Y., Arbel R., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. 2002, 84-A:2123-2134.
14. Kim S.E., Song S.H., P Y., Yun, Choi B.J., Kwon I.K., Bae M.S., Moon H.J., Kwon Y.D. The effect of immobilization of heparin and bone morphogenic protein-2 (BMP-2) to titanium surfaces on inflammation and osteoblast function. Biomaterials 2010, 32:366-373.
15. Russell R.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
16. Douglas D.L., Duckworth T., Russell R.G., Kanis J.A., Preston C.J., Preston F.E., Preston M.A., Woodhead J.S. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980, 1:1043-1047.
17. Mundy G.R., Yoneda T. Bisphosphonates as anticancer drugs. N. Engl. J. Med. 1998, 339:398-400.
18. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C., Yanover M.J., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990, 323:73-79.
19. Garcia-Merco C., Serrano S., Nacher M., Farre M., Diez A., Marinoso M.L., Carbonell J., Mallibovsky L., Nogues X., Ballester J., Aubia J. Effect of alendronate on cultured normal human osteoblasts. Bone 1998, 22:233-239.
20. Kodama T., Goto T., Miyazaki T., Takahashi T. Bone formation on apatite-coated titanium incorporated with bone morphogenetic protein and heparin. Int. J. Oral. Maxillofac. Implants. 2008, 23:1013-1319.
21. Att W., Hori N., Takeuchi M., Ouyang J., Yang Y., Anpo M., Ogawa T. Time-dependent degradation of titanium osteoconductivity: an implication of biological aging of implant materials. Biomaterials 2009, 30:5352-5363.
22. Att W., Hori N., Iwasa F., Yamada M., Ueno T., Ogawa T. The effect of UV-photofunctionalization on the time-related bioactivity of titanium and chromium-cobalt alloys. Biomaterials 2009, 30:4268-4276.
23. Igarashi Y., Lee M.Y., Matsuzaki S. Acid phosphatases as markers of bone metabolism. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2002, 781:345-358.
24. Tengvall P., Skoglund B., Askendal A., Aspenberg P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials 2004, 25:2133-2138.
25. Wermelin K., Tengvall P., Aspenberg P. Increasing effect up to 8 weeks after insertion. Acta. Orthop. 2007, 78:385-392.
26. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., Dacquin R., Mee P.J., McKee M.D., Jung D.Y., Zhang Z., Kim J.K., Mauvais-Jarvis F., Ducy P., Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
27. Choi S.T., Kim J.H., Kang E.J., Lee S.W., Park M.C., Park Y.B., Lee S.K. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology 2008, 47:1775-1779.
28. Teitelbaum S. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
29. Kwon Y.D., Karbach J., Wagner W., Al-Nawas B. Peri-implant parameters in head and neck reconstruction: influence of extraoral skin or intraoral mucosa. Clin. Oral. Implants Res. 2010, 21:316-320.